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Abstract
Owing to its noninvasive collection, saliva
is considered as a potent diagnostic fluid. The
goal of this study was to investigate the modifi-
cation of the salivary proteome occurring in
type 1 diabetes to highlight potential biomarkers of
the pathology. High-resolution two-dimensional
gel electrophoresis and matrix-assisted laser
desorption/ionization time-of-flight mass spec-
trometry were combined to perform a large-
scale analysis. The proteomic comparison of
saliva samples from healthy subjects and poorly
controlled type 1 diabetes patients revealed a
modulation of 23 proteins. Fourteen isoforms of
α-amylase, one prolactin inducible protein,
three isoforms of salivary acidic protein-1, and
three isoforms of salivary cystatins SA-1 were
detected as under expressed, whereas two iso-
forms of serotransferrin were over expressed in
the pathological condition. The proteins under
expressed were all known to be implicated in
the oral anti-inflammatory process, suggesting
that the pathology induced a decrease of non-
immunological defense of oral cavity. As only
particular isoforms of proteins were modulated,
type 1 diabetes seemed to differentially affect
posttranslational modification.
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Introduction
Saliva is a biological fluid of great potential
in clinical medicine (1,2) owing to opportunity
of noninvasive, stress-free, simple, and safe
collection. As modification of the salivary
composition was demonstrated in pathologi-
cal disorders, the interest to study systemic
diseases that affect salivary gland function is
growing (3). For example, diabetes mellitus
was shown to lead to marked dysfunction of
the secretory capacity of the salivary glands
and then may be responsible for the increased
susceptibility to oral infection (4). Type 1 dia-
betes is also known to affect oral homeostasis,
and several studies showed the prevalence of
gingival inflammation in diabetic patient. Both
plaque and gingival indices, bleeding scores,
probing depth, loss of attachment, and number
of missing teeth were demonstrated to increase
in diabetic patients (5), whereas all measured
parameters of periodontal status were affected
in type 1 diabetic adolescents (6).
Until recently, the study of salivary protein
modification occurring in type 1 diabetes was
mainly based on techniques targeting specific
proteins. For instance, using enzymatic assays,
salivary concentration of aminotransferases
and lactate deshydrogenase was found to
increase in type 1 diabetic patients when com-
pared to healthy subjects (7,8). Similarly, the
use of enzyme-linked immunosorbent assay
(ELISA) allowed the specific detection of glu-
tamic acid decarboxylase autoantibodies in
oral fluid of type 1 diabetic patients (9,10).
However, such approaches do not allow for a
comprehensive characterization of the sali-
vary composition. To obtain more systematic
insights into changes in the whole saliva
composition, protemic tools were recently
introduced. The first bidimensional protein
map, combined to mass spectrometry, was pro-
duced to compare the protein composition
between human-acquired enamel pellicle and
whole saliva. Although this work revealed a
relatively simple protein profile and identified
only 7 different proteins (11), further investiga-
tion allowed the construction of a reference sali-
vary protein map cumulating nearly 600 protein
spots of which more than 300 were identified
(12–16). By comparison to other proteomes, the
whole salivary proteome appears to recruit a
relatively low number of different protein
accessions but display extensive posttransla-
tional modification of these proteins. A typical
example concerns the salivary α-amylase, that
is present simultaneously as well as under
native, glycosylated, or truncated isoforms as
under low-molecular-weight forms but show-
ing both N- and C-terminal sequences, lead-
ing to hypothesize the occurrence of internal
deletions (17).
To date, differential comparison between
proteome from healthy and diseased subjects
was initiated to identify proteins that could be
used as biomarkers (18). However, owing to
the emerging complexity of salivary proteome,
and despite the absence of knowledge con-
cerning its functional meaning, the occurrence
of multiple isoforms raises the question of their
potential use as biomarkers. The present work
aimed at investigating modification of the sali-
vary proteome occurring in type 1 diabetes,
with special attention to track changes in pat-
terns of isoforms for identified proteins. For
this purpose, to separate, compare, and iden-
tify proteins between patients, we combined,
respectively, high-resolution bidimensional gel





Immobiline dry strip gels (180 mm) were
from Amersham Biosciences (Orsay, France),
protease inhibitor cocktail from Roche (Meylan,
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France), modified sequencing grade trypsin
from Promega (Charbonnieres, France), C18
Zip-Tip™ from Millipore (Bedford, MA) and
kit for protein concentration measurement
from Pierce (Rockford, IL). Other high purity
reagents were from Sigma (L’Isle d’Abeau,
France) or Bio-Rad (Richmond, CA).
Subjects
The type 1 diabetes group encompassed eight
patients with an average age of 35.6 ± 9.9 yr.
The disease duration was superior to 5 yr 
and patients had a poorly controlled insulin-
dependent diabetes (glycated hemoglobin
HbA1C >8%). The control group was consti-
tuted of eight healthy individuals of similar
age (34.7 ± 8.2 yr) showing no active disease,
no history of drug treatment or therapy within
the previous months, and no history of dia-
betes. Both groups did not manifest clinical
signs of intraoral inflammation and had a good
buccal hygiene.
Collection of Saliva
The study was approved by the Ethics
Committee of the CHU of Montpellier. Whole
saliva was collected 2 h after breakfast time,
smooth tooth brushing, and rinsing mouth
with water 15 min before collection. Stimu-
lated saliva was collected for 5 min by chew-
ing on paraffin wax and spitting intermittently
in tubes containing a protease inhibitor cock-
tail and maintained on ice. After collection,
samples were frozen at –20°C.
Protein Extraction
Samples were centrifuged at 10,000g and at
4°C for 15 min to eliminate mucines and
avoid any oral debris. Proteins were precipi-
tated using 90% acetone (v/v), 10% TCA
(v/v), and 0.07% 2-mercaptoethanol (v/v).
After incubation at –20°C for 2 h, insoluble
material was centrifuged at 37,000g. Pellets
were washed three times with pure acetone
containing 2-mercaptoethanol, air-dried and
solubilized in 9 M urea, 4% CHAPS (w/v),
0.05% Triton X-100 (v/v), and 65 mM DTT.
Protein amount was estimated using the Brad-
ford assay (19).
Two-Dimensional Gel Electrophoresis
Precast IPG strips (pH 3.0–10.0 NL) gradient
were rehydrated overnight with 200 µg of pro-
tein sample. Isoelectric focusing was carried
out using the IPGphor isoelectric focusing
system (Amersham Biosciences, Orsay, France)
for a total of ca. 50,000 V.h. Thereafter, strips
were equilibrated for 15 min in 8 M urea, 
50 mM Tris-HCl buffer at pH 8.8, 30% glycerol
(v/v), 2% SDS (w/v), and 65 mM DTT, and
finally for 15 min in the same solution excepted
that DTT was replaced by 13.5 mM iodoac-
etamide. Proteins were finally separated on
12% SDS-polyacrylamide gels, at constant volt-
age (150 V) and at 10°C, using an Iso-DALT
electrophoresis unit (Amersham Biosciences,
Orsay, France). Gels were stained with colloidal
Coomassie blue. Gel images were digitalized at
300 dpi with a GS 710 densitometer (Bio-Rad,
Hercules, CA).
Image Analysis
Gel images were analyzed using the Progen-
esis Workstation software (Nonlinear Dynamics,
UK). First, gels from healthy donors and dia-
betic patients were aggregated into two sepa-
rate groups. The common area on all gels was
selected for spot detection. For each group, the
gel with the highest number of spots was auto-
selected as reference gel. Images of gels were
first warped to this gel before matching spots.
An average master gel was thus created for
each group including all spots detected in 
individual gels. For comparative analysis, the
intensity of spots was measured by the volume
(expressed as percentage of total volume of all
spots on respective gels) and data were sub-
mitted to Student’s t-test for spot selection.
One way ANOVA were also used for spot
selection and led to similar conclusions.
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In-Gel Digestion
Spots were excised from gels by hand. The
protocol of in-gel digestion is adapted from
ref. 20 and was realized by a Packard Multi-
probe II liquid handling robot (Perkin Elmer,
Courtaboeuf, France). Protein excised spots
from the stained gels were washed succes-
sively with water, 25 mM ammonium bicar-
bonate, HPLC grade acetonitrile/25 mM
ammonium bicarbonate (1:1 v/v), and acetoni-
trile to remove remaining contaminants and to
destain the proteins. The gel fragments were
dried at 37°C. Digestion was carried out at
37°C for 5 h with 10 µL of 0.0125 µg, 1 µL
trypsin (sequencing grade, modified; Promega)
in 25 mM ammonium bicarbonate (pH 7.8).
The resulting tryptic fragments were extracted
twice with 50 µL of acetonitrile/water 
(1:1 v/v) containing 0.1% trifluoroacetic acid
for 15 min. The pooled supernatants were con-
centrated to a final volume of ca. 20 µL by
heating at 37°C for ca. 5 h. The tryptic pep-
tides were desalted and concentrated to a final
volume of 3 µL with Zip-TipTM C18 (Milli-
pore), according to the manufacturer’s proto-
col and immediately spotted onto the MALDI
target by the robot.
MALDI Mass Spectrometry Analysis
α-Cyano-4-hydroxycinnamic acid matrix
was prepared at half saturation in acetoni-
trile/water (1:1 v/v) acidified with 0.1% tri-
fluoroacetic acid. 0.8 µL of each sample was
mixed with 0.8 µL of the matrix and the mix-
ture was immediately spotted on the MALDI
target and allowed to dry and crystallize. The
analyses were performed on a BiFlex III
MALDI-TOF mass spectrometer (Bruker Dal-
tonics, Bremen, Germany). Reflector spectra
were obtained automatically with the AutoX-
ecute™ mode over a mass range of 700 to
3500 Da in the short-pulsed ion extraction
mode using an accelerating voltage of 19 kV.
Spectra from 200 laser shots were summed 
to generate a peptide mass fingerprint for
each protein digest. Two peptide ions gener-
ated by the autolysis of trypsin (842.5099 and
2211.1046) were used as internal standards
for calibrating the mass spectra. Automatic
annotation of monoisotopic masses was per-
formed using Bruker’s SNAP procedure.
Identification by Database Search
We used the MASCOT search engine soft-
ware (Matrix Science, London, UK) running on
a local server to search NCBInr database. The
following parameters were used for database
search: (1) taxonomy search restrained to
mammalia, (2) mass tolerance of 50 ppm, (3) a
minimum of five peptides matching to the
protein, (4) one missed cleavage allowed, (5)
carbamidomethylation of cysteine as fixed
modification, and (6) oxidation of methionine




Type 1 diabetes is a complex endocrine dis-
ease with a number of associated pathologies
like neuropathy, cardiovascular disease, or
oral pathologies (21) and care must be taken
when selecting diabetic patients to minimize
protein variation specifically induced by these
associated pathology. To ensure homogeneity
within the group, the schedule of conditions
was restricted to 20- to 45-yr-old patients,
showing diabetes type 1 since at least 5 yr old
(Table 1). In addition, as major biochemical
changes are known in poorly controlled insulin-
dependent diabetes (22), we choose patients
with poorly controlled insulin-dependent
diabetes (HbA1C >8%; Table 1) to evaluate
the impact of glucose metabolism on the 
salivary proteins synthesis.
As no previous information was available
concerning the stability of saliva samples,
preliminary experiments were performed on
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various saliva samples. No changes in protein
profile could be detected after storage up to 7 d
at 4°C or up to 4 mo at –20°C (not shown).
Therefore, in the present work, to ensure an
increased protection against eventual degra-
dation, samples were immediately frozen at
–20°C after collection and processed within
10 d. To minimize experimental variation,
standardized procedures were selected, includ-
ing simultaneous processing of the two kinds
of samples, and the overall reproducibility of
the procedure was estimated. For this latter
purpose, triplicates of samples were com-
pared. Concerning the saliva protein concen-
tration, no significant variation could be
detected between the two studied groups, con-
trolled and diabetic. As no presence of
hemoglobin could be visually detected, a com-
parison on the basis of identical protein
amounts loaded on gels can be allowed.
The variation coefficient for the number of
detected spots amounted to 5 and 88% of
spots could be matched on every gel. For
these matched spots, the average variation
coefficient for intensity was of 35%. This
showed that protein separation was robust
and suggested that significant variations could
be identified for fold changes of a factor 2. 
A typical two-dimensional gel is shown on
Fig. 1. Similar numbers of spots were detected
on individual gels from healthy subjects (243
± 36 spots) and diabetic patients (255 ± 55
spots). Master gels for the two groups were
found to share 214 spots that were selected
for subsequent statistical analysis. As illus-
trated on Fig. 2, it should also be emphasized
that not every gel displayed all these spots
(like spot 27) and that intrapopulation differ-
ences in the abundance of some spots were
also observable (like for spot 4). Nevertheless,
statistical analysis showed that 23 spots dis-
played significantly different accumulation
levels between the two groups (Fig. 1), with
fold changes exceeding, respectively, 7 and 10
for spots, respectively, over-accumulated and
under-accumulated in saliva of diabetic
Table 1
Clinical Details for Diabetic Patientsa
Patient Diabetes
number Sex Age duration HbA1c
9 M 24 5 13.7
10 M 45 12 10.7
11 M 26 6 11.1
12 F 45 10 10.5
13 F 39 8 9.1
14 M 42 20 10.2
15 M 42 37 8.1
16 M 22 8 12.0
aPatient 9–16 included sex (M refer to male and F to
female), age (years), diabetes duration (years), and
percentage of glycated haemoglobin (HbA1c).
Fig. 1. Two-dimensional map of human salivary pro-
teins from diabetic type 1 patient.Two hundred micro-
grams of proteins were resolved using pH 3.0–10.0 NL
IPG and 12% SDS-PAGE and gel was stained with 
colloidal Coomassie blue. Spots in A–E were identified
by MALDI-TOF/MS as α-amylase (A), prolactin
inducible protein (B), salivary acidic protein-1 (C),
salivary cystatin SA-1 (D), and serotransferin (E).
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patients (Table 2). Protein identification by
MALDI-TOF/MS showed that they corre-
sponded to five different accessions in
databases, of which four were identified in
multiple spots. Therefore, the salivary pro-
teome appears to differ in diabetic patients,
but the differences both concern a relatively
limited part of the proteome (ca. 10% of spots)
and are mainly restricted to some isoforms of
a few proteins. However, as the analysis was
performed only on spots detected on master
gels from both groups, the possibility of
larger variations, through specific presence of
given spots in only one group, cannot be
ruled out.
Proteins Under-Accumulated in Saliva
From Diabetic Patients Are Involved 
in Oral Anti-Inflammatory Processes
The largest group (Fig. 1A) included 14
spots of α-amylase (Swiss-Prot P04745). These
spots were detected in nearly all subjects and
showed an average fivefold under-accumula-
tions in diabetic patients (Table 2). α-Amylases
belong to the family of α-1,4-glucan-4-glu-
canohydrolases that catalyze the cleavage of
α-D-(1-4) glycosidic bonds in starch and
related carbohydrates (23). It constitutes one
of the major secretory products of the pan-
creas and salivary glands (24). Amylases
would also be involved in anti-inflammatory
reactions, such as those caused by the release
of histamine and similar substances, and 
α-amylase is used, among other medicines, in
the treatment of some lung problems includ-
ing asthma and emphysema. Furthermore, in
solution, α-amylase has been shown to bind
with high affinity to oral viridans streptococci,
an interaction that may lead to the clearance
and/or adherence of these bacteria in the oral
cavity (25). Therefore, it could be speculated
whether the under-accumulation of α-amylase
spots in diabetic patients could be related 
to changes in oral anti-inflammatory status. In
this view, it must be pointed out that all
under-accumulated α-amylase spots exhibit a
molecular weight lower than that of native 
α-amylase (56 kDa). The occurrence of such
Fig. 2. Intrapopulation variability of protein accumulation. Example of salivary acidic protein-1 isoforms
showing quantitative differences for diabetic patients (DP) and healthy subjects (HS).
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low-molecular-weight isoforms was reported
in several recent works (12–14,16,17). Accord-
ing to these data (16,17), the 14 spots shown
here to be under-accumulated in diabetic
patients would correspond to about 30% of the
previously described low-molecular-weight
isoforms. This suggests that the disease would
affect selectively only a part of α-amylase iso-
forms, the biological role of such isoforms still
remains to be investigated.
The second group of proteins under-accu-
mulated in type 1 diabetes was composed of
isoforms of two different salivary cystatins:
three spots identifying the salivary acidic pro-
tein-1 (Swiss-Prot P01036; Fig. 1C) and three
spots of salivary cystatin SA-1 (Swiss-Prot
P01037; Fig. 1D). As for α-amylase, these spots
were detected in nearly all subjects but aver-
age under-accumulation in diabetic patients
was two-times lower for salivary acidic pro-
tein-1 than for cystatin SA-1 or α-amylase
(Table 2). Salivary cystatins constitute a large
group of proteins that are potent inhibitors 
of cystein peptidases. Salivary acidic protein-1
belongs to the cystatin S subgroup, inhibits
papain and ficin, and is involved in the preva-
lence of periodontal disease (26). Cystatin SA-
1 is part of the cystatin SN subgroup that
differs from cystatins S by their specificity.
Beside the control of proteolytic events in
vivo, both subgroups are known to be
involved in the regulation of inflammatory
processes (27) with examples concerning the
nonimmunological defense against oral
microorganisms like Streptococcus salivarus (28)
and the regulation of inflammatory processes
in the oral cavity and ocular tissues (25). On
this basis, it can be hypothesized that type 1
diabetes could induce a specific decrease in
nonimmunological defense of the oral cavity.
Interestingly, these under-accumulated cys-
tatins cover most of the isoforms previously
detected for the acidic protein-1 and the cys-
tatin SA-1 in the saliva proteome (16), but
other subgroups of cystatins appear to remain
unaffected in diabetic patients. By this way,
and conversely to α-amylase where only a
part of isoforms is sensitive to diabetes, the
disease would exert a limited control of the
accumulation of cystatins by affecting most
products of only some cystatin genes. 
The last spot under-accumulated in diabetes
type 1 identified a prolactin-induced protein
(PIP) (Swiss-Prot P12273; Fig. 1B). This spot
was detected in only half diabetic patients
where it showed an average fivefold under-
accumulations (Table 2). The PIP is believed
to originate from a limited set of tissues,
including breast and salivary glands, and was
previously used as a clinical marker for the
diagnosis of metastatic tumors of unknown
origin (29). It was also proposed to be involved
in the nonimmunological host defense by
binding to bacteria (30). On another hand,
only one spot of PIP was shown here to be
responsive to diabetes, whereas the protein
was observed in several spots (16). Therefore,
this suggests that, as pointed above for α-amy-
lase, only a part of PIP isoforms would be
affected by the disease. 
It is striking that, for all the under-accumu-
lated proteins, previous data point to their
possible involvement in nonimmunological anti-
inflammatory processes of oral cavity. Although
no oral complication was observed in the dia-
betic patient group, this suggests that a general-
ized decrease in the nonimmunological defense
could be associated to the disease and possibly
account for the prevalence of oral infections that
is known in patients with type 1 diabetes. In
this view, the decrease in the defense would
result from complex regulations concerning
both specific isoforms (in the case of α-amylase
and PIP) and the overall secretion (for some
subgroups of cystatins). Numerous reports
describe the occurrence of multiple isoforms for
these proteins (12–14, 16, 17, 19, 24, 25, 36–38,
40–44). However, both the molecular basis for
these regulations by diabetes and their func-
tional consequences remain to be elucidated.
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Table 2
Protein Spots Showing Significant Differences (p < 0.05) in Their Accumulation 
in Saliva From Diabetic Patients and Healthy Subjectsa
Mascot Number Accession
Spot Protein PMF of matching Swiss MW Matchs Matchs Fold p
number name score peptides Area prot (kDa) pI HS DP change value
1 Salivary 182 10 D P01037 14.3 6.92 8 8 –1.9 0.041
cystatin
SA-1
4 Salivary 132 14 C P01036 14.2 4.83 8 7 –2.0 0.049
acidic
protein-1
6 Salivary 165 9 D P01037 14.2 4.83 8 8 –2.3 0.032
cystatin
SA-1
7 Salivary 158 14 C P01036 14.2 4.83 8 7 –3.6 0.018
acidic
protein-1
15 Salivary 210 22 A P04745 55.9 6.34 8 8 –2.6 0.016
α-amylase
17 Salivary 140 15 A P04745 55.9 6.34 8 8 –2.3 0.013
α-amylase
27 Salivary 202 17 C P01036 13.5 5.47 8 8 –2.6 0.031
acidic
protein-1
29 Salivary 185 19 A P04745 55.9 6.34 8 8 –3.8 0.012
α-amylase
33 Salivary 236 21 A P04745 55.9 6.34 8 8 –3.7 0.025
α-amylase
47 Salivary 176 14 A P04745 55.9 6.34 8 7 –2.8 0.041
α-amylase
48 Salivary 179 14 A P04745 55.9 6.34 8 8 –3.8 0.033
α-amylase
49 Salivary 248 19 A P04745 55.9 6.34 7 3 –8.3 0.019
α-amylase
53 Salivary 161 15 A P04745 55.9 6.34 6 6 –8.2 0.009
α-amylase
58 Salivary 142 11 A P04745 55.9 6.34 7 7 –6.5 0.019
α-amylase
67 Prolactin- 155 8 B P12273 13.5 5.47 7 4 –5.9 0.040
inducible
protein
71 Salivary 127 14 A P04745 55.9 6.34 6 5 –4.3 0.040
α-amylase
96 Salivary 140 12 A P04745 55.9 6.34 8 8 –3.8 0.010
α-amylase
(Continued)
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Table 2 (Continued)
Mascot Number Accession
Spot Protein PMF of matching Swiss MW Matchs Matchs Fold p
number name score peptides Area prot (kDa) pI HS DP change value
102 Salivary 141 8 D P01037 14.3 6.92 8 8 –10.8 0.047
cystatin
SA-1
104 Salivary 214 17 A P04745 55.9 6.34 8 7 –5.6 0.026
α-amylase
124 Salivary 231 19 A P04745 55.9 6.34 8 7 –10.3 0.033
α-amylase
139 Salivary 285 22 A P04745 55.9 6.34 8 6 –6.0 0.014
α-amylase
307 Serotransferrin 189 17 E P02787 75.2 6.70 3 2 7.1 0.000
309 Serotransferrin 204 18 E P02787 75.2 6.70 3 3 5.3 0.023
aThe area column refers to the box of localization in Fig. 1. The significance threshold of the Mascot database
search restrained to mammalia is of 64. Negative fold changes refer to under-accumulated spots in saliva of dia-
betic patients. p value was obtained using Student’s t-test. MW corresponds to the theorical molecular weight
of the proteins.
Over-Accumulated Proteins in Saliva 
From Diabetic Patients
Two spots of serotransferrin (Swiss-Prot
P02787; Fig. 1E) were found to display an
average sixfold over-accumulation in saliva 
of diabetic patients. However, these spots
were observed in only a minority of subjects
(Table 2), suggesting the possible occurrence
of different responses according to the patients.
Transferrins are iron binding transport proteins
expressed in the liver and secreted in plasma
(31). The accumulation of these proteins in
blood was previously described for diabetic
patients in response to oxidative stress (32,33).
At first sight, this result appears to be surpris-
ing whereas serotransferrin was not described
to be secreted into saliva. A hypothesis of its
presence in saliva could be a blood contami-
nation. However, considering that we used a
standard protocol described in other salivary
proteome publication (11), and that we have
carefully verified the colorless of our saliva
samples, this hypothesis is improbable. Also,
we can notify that a number of plasma pro-
teins are known to be transferred into saliva by
exudation of plasma in the oral cavity (34,35).
Moreover, if the presence of serotransferrin in
saliva is rare, it has already been reported in
nonstimulating whole saliva investigated
using two-dimensional liquid chromatography
and mass spectrometry (15,36). Considering
that the amount of plasmatic protein in saliva
is proportional to the blood concentration of
free protein (37), we can hypothesize that the
accumulation of transferrin in saliva might be
related to an increase in free plasmatic sero-
transferrin in diabetic patients.
Concluding Remarks
The present work shows, for the first time,
that the salivary proteome of diabetic patients
differs from healthy subjects. It is noteworthy
that type 1 diabetes appears to induce rela-
tively limited and subtle changes in the saliva
proteome. Moreover, beside the rare posi-
tive markers observed, these changes offer
more functional information than candidate
markers. Of physiological interest, lower
abundances of given α-amylase, cystatin, and
PIP isoforms are demonstrated to occur 
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concomitantly in diabetic patients. According
to available data concerning the role of these
proteins in anti-inflammatory processes, this sit-
uation is proposed to reveal a decrease of the
nonimmunological defense of the oral cavity.
On another hand, this work illustrates also that
the proteomics technology has the power 
to evidence events undetectable when using
global protein approaches, the latter lacking to
address individual isoforms. In this view, the
saliva proteomics can be speculated simultane-
ously to constitute an efficient diagnostic tool
and to open new challenges for deciphering the
function of responsive isoforms.
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